Greene D A, Brown M J, Braunstein S N, Schwartz S S, Asbury A K, Winegrad A I
Diabetes. 1981 Feb;30(2):139-47. doi: 10.2337/diab.30.2.139.
The use of electrophysiological (EP) tests as the primary basis for determining outcome in clinical trials of therapy for symptomatic diabetic polyneuropathy, and the frequently short duration of such trials, is based on assumptions at variance with the pathology and natural history of this disorder and with the evidence that the commonly employed EP tests predominantly reflect the status of the large myelinated nerve fibers. The course of painful, distal symmetrical, primarily sensory polyneuropathy was studied in nine chronic diabetics, aged 21--59 yr, selected for the absence of other forms of diabetic neuropathy, other causes of neuropathy, and other significant illness. All were treated with modifications of diet, insulin, and a daily multivitamin tablet, and, on a randomized basis, also received either placebo or myo-inositol tablets. Initially, and after 2, 4, and 6 mo, a standardized questionnaire was used to assess symptoms, and a standardized neurological examination and battery of EP tests were performed. A minimum of 6 mo was found necessary to assess the clinical course of this syndrome. Clinical improvement occurred in both legs and arms in four patients, as judged by improvement both in symptoms and in the extent of deficits in pinprick and temperature perception; abnormalities in sensory modalities mediated by large myelinated fibers, however, were generally unaltered after 6 mo. A nonuniform distribution of abnormal EP tests of sensory components of the commonly studied nerves of the leg and arm was demonstrated in the study group at the outset, and clinical improvement was not accompanied by evidence of any consistent pattern of improvement in the initially abnormal EP tests. A significant fraction of chronic diabetics with painful, distal symmetrical, primarily sensory polyneuropathy selected by standard criteria appear to have potential for clinical improvement over 6 mo, but primarily in sensory modalities that make it inappropriate to use the common EP tests as the primary basis of judging outcome.
在有症状的糖尿病性多发性神经病治疗的临床试验中,将电生理(EP)测试作为确定疗效的主要依据,且此类试验的持续时间常常较短,这是基于与该疾病的病理和自然史以及与以下证据相矛盾的假设:常用的EP测试主要反映的是有髓大神经纤维的状态。对9名年龄在21至59岁的慢性糖尿病患者的疼痛性、远端对称性、主要为感觉性多发性神经病的病程进行了研究,这些患者被选定为不存在其他形式的糖尿病性神经病、神经病的其他病因以及其他重大疾病。所有患者均接受饮食、胰岛素和每日复合维生素片的调整治疗,并在随机基础上,还接受安慰剂或肌醇片治疗。最初,以及在2、4和6个月后,使用标准化问卷评估症状,并进行标准化神经系统检查和一系列EP测试。发现至少需要6个月来评估该综合征的临床病程。根据症状以及针刺觉和温度觉缺损程度的改善判断,4名患者的双腿和双臂均出现临床改善;然而,由有髓大纤维介导的感觉模式异常在6个月后通常未改变。在研究组开始时,腿部和手臂常见研究神经的感觉成分的异常EP测试呈现出不均匀分布,并且临床改善并未伴有最初异常的EP测试出现任何一致改善模式的证据。通过标准标准选定的患有疼痛性、远端对称性、主要为感觉性多发性神经病的慢性糖尿病患者中,有很大一部分似乎在6个月以上有临床改善的潜力,但主要是在感觉模式方面,这使得将常见的EP测试作为判断疗效的主要依据并不合适。